<DOC>
	<DOCNO>NCT01393951</DOCNO>
	<brief_summary>This trial design blind , randomize parallel group study investigate clinically recommended dosage ASP7374 base comparison immunogenicity safety among two dos subcutaneous ASP7374 one dose intramuscular ASP7374 healthy adult .</brief_summary>
	<brief_title>A Study Evaluate Immune Response ASP7374 Its Safety Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Body weight : Female : ≥40.0 kg , &lt; 70.0 kg , Male : ≥50.0 kg , &lt; 80.0 kg BMI : ≥17.6 , &lt; 26.4 Healthy , judge investigator subinvestigator base result physical examination ( subjective symptom objective finding ) test obtain Scheduled receive another vaccine study participation period Received influenza vaccine within 180 day prior study Received schedule receive live vaccine within 28 day prior vaccination study vaccine , receive schedule receive inactivate vaccine toxoid within 7 day prior vaccination study vaccine Diagnosis immune deficit past , family member ( within third degree kinship ) diagnosis congenital immunodeficiency syndrome Past history anaphylactic shock allergic reaction generalize eruption due food drug ( include vaccine ) allergy , fever ≥ 39.0°C within 2 day previous vaccination ( influenza vaccine others ) Female subject breastfeeding , pregnant , possibly pregnant , plan become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Recombinant Influenza hemagglutinin vaccine</keyword>
</DOC>